PTK7 Protein is Decreased in Epithelial Ovarian Carcinomas with Poor Prognosis

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2015 Jan 1

PMID 25550828

Citations 21

Authors

Haiyan Wang

Guimei Li

Yongxiang Yin

Jianjun Wang

Hai Wang

Wei Wei

Qing Guo

Henghui Ma

Qunli Shi

Xiaojun Zhou

Jiandong Wang

Affiliations

Soon will be listed here.

Abstract

Epithelial ovarian cancer is the most common tumor of ovary. PTK7 plays an important role in tumors. Till now, there is no report about the role of PTK7 in ovarian epithelial neoplasms. This study aims to investigate the expression of PTK7 protein in epithelial ovarian tumors, and its relationship with clinical pathological characteristics. In this study, immunohistochemical staining was used to detect the expression of PTK7 protein in 14 samples of normal fallopian tube epithelium and 204 cases of epithelial ovarian tumor. The relationship between the expression of PTK7 and pathological indicators was statistically analyzed. Kaplan-Meier survival function was used to analyze the prognosis. The expression of PTK7 was found in 92.86% (13/14) of normal fallopian tube epithelium and 45.10% (92/204) of epithelial ovarian tumor tissues. The expression level of PTK7 was significantly decreased from the benign, the intermediate type, to malignant ovarian epithelial tumors (P < 0.001), and decreased from the normal control group to serous carcinomas (P < 0.001). The expression of PTK7 was significantly different in type I and type II epithelial ovarian carcinomas (P < 0.001). PTK7 protein expression was associated with clinical stages (P = 0.038) and metastases (P = 0.038) in ovarian borderline serous tumors. PTK7 protein expression was associated with clinical stages (P = 0.011), WHO grading (P = 0.004), and MDACC grading (P < 0.001) in ovarian serous carcinomas. The survival analysis showed that patients with negative expression of PTK7 protein had a poorer outcome than those with positive expression (P = 0.017). These results indicate that PTK7 protein may be a tumor suppressor and a potential prognostic marker in ovarian serous carcinomas.

Citing Articles

PTK7: an underestimated contributor to human cancer.

Jin Z, Guo T, Zhang X, Wang X, Liu Y Front Oncol. 2024; 14:1448695.

PMID: 39474113 PMC: 11518688. DOI: 10.3389/fonc.2024.1448695.

Therapeutic advances of targeting receptor tyrosine kinases in cancer.

Tomuleasa C, Tigu A, Munteanu R, Moldovan C, Kegyes D, Onaciu A Signal Transduct Target Ther. 2024; 9(1):201.

PMID: 39138146 PMC: 11323831. DOI: 10.1038/s41392-024-01899-w.

Recent insights into the therapeutic strategies targeting the pseudokinase PTK7 in cancer.

Dessaux C, Ganier L, Guiraud L, Borg J Oncogene. 2024; 43(26):1973-1984.

PMID: 38773263 PMC: 11196218. DOI: 10.1038/s41388-024-03060-x.

FOXP4-mediated induction of PTK7 activates the Wnt/β-catenin pathway and promotes ovarian cancer development.

Ji J, Qian Q, Cheng W, Ye X, Jing A, Ma S Cell Death Dis. 2024; 15(5):332.

PMID: 38740744 PMC: 11091054. DOI: 10.1038/s41419-024-06713-7.

Multiomics characterization implicates PTK7 in ovarian cancer EMT and cell plasticity and offers strategies for therapeutic intervention.

Raivola J, Dini A, Karvonen H, Piki E, Salokas K, Niininen W Cell Death Dis. 2022; 13(8):714.

PMID: 35977930 PMC: 9386025. DOI: 10.1038/s41419-022-05161-5.

References

Yen W, Williams M, Periasamy A, Conaway M, Burdsal C, Keller R . PTK7 is essential for polarized cell motility and convergent extension during mouse gastrulation. Development. 2009; 136(12):2039-48. PMC: 2685725. DOI: 10.1242/dev.030601. View

Mossie K, Jallal B, Alves F, Sures I, Plowman G, Ullrich A . Colon carcinoma kinase-4 defines a new subclass of the receptor tyrosine kinase family. Oncogene. 1995; 11(10):2179-84. View

Meng L, Sefah K, ODonoghue M, Zhu G, Shangguan D, Noorali A . Silencing of PTK7 in colon cancer cells: caspase-10-dependent apoptosis via mitochondrial pathway. PLoS One. 2010; 5(11):e14018. PMC: 2982840. DOI: 10.1371/journal.pone.0014018. View

Gorringe K, Boussioutas A, Bowtell D . Novel regions of chromosomal amplification at 6p21, 5p13, and 12q14 in gastric cancer identified by array comparative genomic hybridization. Genes Chromosomes Cancer. 2004; 42(3):247-59. DOI: 10.1002/gcc.20136. View

Lin Y, Zhang L, Wang X, Xing X, Cheng X, Dong B . PTK7 as a novel marker for favorable gastric cancer patient survival. J Surg Oncol. 2012; 106(7):880-6. DOI: 10.1002/jso.23154. View

Muller-Tidow C, Schwable J, Steffen B, Tidow N, Brandt B, Becker K . High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Clin Cancer Res. 2004; 10(4):1241-9. DOI: 10.1158/1078-0432.ccr-0954-03. View

Jung J, Ji A, Lee J, Kim U, Lee S . Organization of the human PTK7 gene encoding a receptor protein tyrosine kinase-like molecule and alternative splicing of its mRNA. Biochim Biophys Acta. 2002; 1579(2-3):153-63. DOI: 10.1016/s0167-4781(02)00536-5. View

Chen R, Khatri P, Mazur P, Polin M, Zheng Y, Vaka D . A meta-analysis of lung cancer gene expression identifies PTK7 as a survival gene in lung adenocarcinoma. Cancer Res. 2014; 74(10):2892-902. PMC: 4084668. DOI: 10.1158/0008-5472.CAN-13-2775. View

Lee S, Strunk K, Spritz R . A survey of protein tyrosine kinase mRNAs expressed in normal human melanocytes. Oncogene. 1993; 8(12):3403-10. View

10.

Pejovic T, Pande N, Mori M, Mhawech-Fauceglia P, Harrington C, Mongoue-Tchokote S . Expression profiling of the ovarian surface kinome reveals candidate genes for early neoplastic changes. Transl Oncol. 2009; 2(4):341-9. PMC: 2781076. DOI: 10.1593/tlo.09199. View

11.

Gobble R, Qin L, Brill E, Angeles C, Ugras S, OConnor R . Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis. Cancer Res. 2011; 71(7):2697-705. PMC: 3070774. DOI: 10.1158/0008-5472.CAN-10-3588. View

12.

Golubkov V, Strongin A . Downstream signaling and genome-wide regulatory effects of PTK7 pseudokinase and its proteolytic fragments in cancer cells. Cell Commun Signal. 2014; 12:15. PMC: 4007575. DOI: 10.1186/1478-811X-12-15. View

13.

Golubkov V, Chekanov A, Cieplak P, Aleshin A, Chernov A, Zhu W . The Wnt/planar cell polarity protein-tyrosine kinase-7 (PTK7) is a highly efficient proteolytic target of membrane type-1 matrix metalloproteinase: implications in cancer and embryogenesis. J Biol Chem. 2010; 285(46):35740-9. PMC: 2975198. DOI: 10.1074/jbc.M110.165159. View

14.

Saha S, Bardelli A, Buckhaults P, Velculescu V, Rago C, St Croix B . A phosphatase associated with metastasis of colorectal cancer. Science. 2001; 294(5545):1343-6. DOI: 10.1126/science.1065817. View

15.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30. DOI: 10.3322/caac.21166. View

16.

Nik N, Vang R, Shih I, Kurman R . Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annu Rev Pathol. 2013; 9:27-45. DOI: 10.1146/annurev-pathol-020712-163949. View

17.

Shin W, Kwon J, Lee H, Kang M, Na H, Lee S . Oncogenic role of protein tyrosine kinase 7 in esophageal squamous cell carcinoma. Cancer Sci. 2013; 104(8):1120-6. PMC: 7657253. DOI: 10.1111/cas.12194. View

18.

Gartner S, Gunesch A, Knyazeva T, Wolf P, Hogel B, Eiermann W . PTK 7 is a transforming gene and prognostic marker for breast cancer and nodal metastasis involvement. PLoS One. 2014; 9(1):e84472. PMC: 3883666. DOI: 10.1371/journal.pone.0084472. View

19.

Piao Z, Lee K, Kim H, Perucho M, Malkhosyan S . Identification of novel deletion regions on chromosome arms 2q and 6p in breast carcinomas by amplotype analysis. Genes Chromosomes Cancer. 2001; 30(2):113-22. View

20.

Shin W, Maeng Y, Jung J, Min J, Kwon Y, Lee S . Soluble PTK7 inhibits tube formation, migration, and invasion of endothelial cells and angiogenesis. Biochem Biophys Res Commun. 2008; 371(4):793-8. DOI: 10.1016/j.bbrc.2008.04.168. View